An observational study in Lymphoma and Hemophagocytic Lymphohistiocytoses, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by University of Alabama at Birmingham · Observational
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
Retrospective, multi-institutional study focused on describing the clinical features, laboratory parameters, treatments, and outcomes among individuals presenting with HLH in the setting of a lymphoma
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 136 across 625 observational studies indexed under Lymphoma.
Browse Lymphoma studies →University of Alabama at Birmingham is the lead sponsor of 1,396 studies on the registry; 284 are open to participants now.
Of its 156 completed or terminated interventional studies of FDA-regulated products, 124 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with diagnosis of Hemophagocytic lymphohistiocytosis (HLH)
A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25>3,900 U/mL and ferritin>1,000 ng/mL)
Exclusion Criteria:
To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+
The investigators will gather data on different treatments received, time to treatment, and other factors and determine which is associated with survival.
Time frame: The participant's survival would be assessed at 180 days from the malignancy diagnosis
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham